David Sterling: You're the one who flagged this — I'm still not sure I believe the framing.
Megan Skiendel: Which part?
David Sterling: That the thymus number is the damning detail. Seven years of improvement is a large effect.
Megan Skiendel: That's exactly the problem. Bryan Johnson runs 100 days of Human Growth Hormone — CJC-1295 with DAC, up to 1.8 IU — his thymus fat fraction shifts by a seven-year equivalent, and he tells Doctor Mike on YouTube it was the worst thing he ever did to his body. A pretty extreme cost, his phrase. He discontinued it. Completely. And he's the founder of Project Blueprint and the Don't Die movement, a guy whose $2 million annual longevity budget — funded by the $800 million Braintree sale to PayPal — is supposed to make this rigorous. The data said yes. His body said catastrophic. That is not a measurement success. That's a measurement system that cannot tell the difference between winning and losing.
David Sterling: Right — but the uncomfortable version is: maybe the thymus number is valid and something else in the protocol caused the damage. That's actually worse. Because then you can't even attribute the failure.
Megan Skiendel: Which is the whole design flaw. One hundred variables, one subject. You cannot isolate anything.
David Sterling: But that's actually the more precise version of the problem, and I want to pin it down before we go further. Because 'you can't isolate anything' is almost too broad. The specific failure with the thymus reading is — imagine your car's oil-pressure gauge reads perfect while the engine is overheating. The oil pressure is real data. It's not lying. You just optimized for the gauge instead of the engine.
Megan Skiendel: The thymus fat fraction shifted. That measurement isn't fabricated.
David Sterling: Exactly — it's real. The thymus is an immune-system gland, the HGH protocol was specifically designed to rejuvenate it, and across three MRIs the fat fraction moved by a seven-year equivalent. That happened. The mistake isn't bad measurement. It's assuming one proxy is a verdict on whole-body health.
Megan Skiendel: Which is — wait, that's actually a different charge than fraud. That's a design error baked into Blueprint from the start.
David Sterling: It is. And here's the transparency gap that nobody's naming: we still don't know what the adverse effects actually were. Johnson told Doctor Mike the cost was 'pretty extreme' — his words — but the sources don't specify which effects. Elevated cortisol? Joint pain? Something metabolic? That ambiguity is itself a data problem. You can't learn from a failure you haven't fully disclosed.
Megan Skiendel: And no longevity trial — not the TAME metformin trial, not anything — is designed around one subject running 100-plus variables simultaneously. So even if Johnson published everything, what generalizes?
David Sterling: Nothing, formally. The HGH case is actually the mild version of this problem, frankly — the one where at least he stopped. The autoimmune gastritis is where the surveillance paradox gets genuinely hard to defend, and that's where I think your read gets sharper than mine.
Megan Skiendel: This is genuinely indefensible, honestly. Low iron — flagged in Bryan Johnson's own datasets, year after year. Not improving despite supplementation. That signal is sitting right there inside Project Blueprint's 100-plus biomarker stack, and the underlying cause is autoimmune gastritis — his immune system destroying the acid-producing cells in his stomach lining, blocking iron absorption entirely. He finds out via stomach biopsy. A biopsy. After all of that.
David Sterling: Wait — the low iron was in the dataset for years?
Megan Skiendel: Years. And he posts on X — I have an autoimmune disease. My stomach is eating itself. That's the quote. So the most expensive personal surveillance system ever built... watched a chronic autoimmune condition develop and logged the downstream symptom without identifying the mechanism. That's not a data gap. That's a synthesis failure.
David Sterling: That's actually the structural indictment, and it's sharper than the HGH case. The HGH failure — he stopped, he disclosed it. The gastritis is a case where the protocol can't even claim credit for the catch, because a biopsy caught it, not the wearables.
Megan Skiendel: And think about who's downstream of this. Picture a 42-year-old founder in San Francisco — reads Johnson's HGH retraction, sees the thymus data, goes to a clinic citing Blueprint as validation, buys HGH. Six months in, resting heart rate climbs, sleep degrades. He stops. But the clinic invoices him for the full twelve-month protocol anyway. He pays. His failure never surfaces publicly because he isn't Bryan Johnson. Nobody updates the model.
David Sterling: That's the cost structure Johnson's transparency actually masks. I mean — the admission becomes content that validates the system, but the anonymous failures stay invisible. And look, tirzepatide: discontinued after roughly three weeks in 2026, wearables caught the elevated heart rate and degraded HRV. That's faster. But it's still another pharmacological failure.
Megan Skiendel: And rapamycin is still in the stack — even though some sources suggest it may be accelerating aging rather than slowing it. Thin evidence, genuinely uncertain, but the fact that it's even a live question and nothing changes? That's not iteration. The surveillance paradox is: $2 million a year, and the signal you needed was there the whole time.
David Sterling: Which brings me back to the framing you opened with — I came in skeptical that the thymus number was the damning detail. I think the actual damning detail is simpler. Johnson called HGH his worst intervention. No replacement product followed that disclosure. That's — actually, wait — that's the one honest data point in the whole story. Every other retraction, the teenage plasma transfusion, tirzepatide, comes with a pivot. The HGH one just... stopped. And engagement on that video almost certainly climbed. So the most important thing Project Blueprint has ever measured might be the engagement rate on its own failures.
Megan Skiendel: I can't argue with that. The gastritis is damning. The rapamycin question is unresolved. But the architecture holds because the admissions are the content. That's the thing I couldn't get clean until just now.
David Sterling: Good talk. Genuinely.
Megan Skiendel: You too.
